Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 12, 2021

DiscernDx NASH liquid biopsy test proves as an alternative to liver biopsy

DiscernDx has reported that preliminary study results from its non-invasive liquid biopsy test for diagnosing early stages of nonalcoholic steatohepatitis (NASH) showed the multi-omics and machine learning combination for NASH diagnosis as an alternative to liver biopsy.

DiscernDx has reported that preliminary study results from its non-invasive liquid biopsy test for diagnosing early stages of nonalcoholic steatohepatitis (NASH) showed the multi-omics and machine learning combination for NASH diagnosis as an alternative to liver biopsy.

Blood samples were collected from 29 centres across the US and Canada forming a cohort of 517 patients suspected of having NASH F2-F4 fibrosis grades.

The liquid biopsy test’s preliminary performance characterised by the area under the receiver operating characteristic (AUROC) in the development set of 90 samples showed exceptional performance in reproducing liver biopsy results, with an AUROC of 0.92.

DiscernDx noted that the liquid biopsy test could be an accurate and non-invasive substitute for liver biopsy for patients suspected of having NASH in the US.

It could lower the requirement for liver biopsy and costly imaging and could aid in earlier disease diagnosis and clinical trials for NASH treatments.

DiscernDx CEO Chris Hall said: “We’re excited to present this data for the first time, as there is a huge unmet medical need for a highly accurate, non-invasive test for early detection of liver fibrosis.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

“Our non-invasive, potentially first-to-market liquid biopsy test is able to diagnose NASH with significant fibrosis with high accuracy, which is critical to avoid unnecessary liver biopsy for patients.”

A progressive and prevalent liver disease, nonalcoholic fatty liver disease (NAFLD) affects around a quarter of adults in the US.

Approximately 20% of NAFLD patients advance to NASH, which can progress into liver cirrhosis. By 2030, it is estimated to be the most frequent cause of liver transplants.

Major predictors of outcomes in NAFLD are liver fibrosis development and progression.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU